| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.7M | — | — |
| Cost of Revenue | $1.2M | — | — |
| R&D Expense | $12.0M | — | -35.8% |
| SG&A Expense | $46.5M | — | +87.6% |
| Operating Income | -$46.0M | — | -5.9% |
| Pre-tax Income | -$47.3M | — | -21.1% |
| Income Tax | $2.2M | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $243.5M | — | — |
| Accounts Receivable | $5.8M | — | — |
| Inventory | $458K | — | — |
| Current Assets | $325.2M | — | — |
| Total Assets | $339.9M | — | — |
| Current Liabilities | $45.1M | — |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$127.0M | — | — |
| Capital Expenditures | $1.9M | — | — |
| Investing Cash Flow | $19.9M | — | — |
| Financing Cash Flow | $164.4M | — | — |
| Free Cash Flow | -$128.8M | — | — |
| Net Income | -$49.5M | +14.1% | -26.6% |
| EPS (Basic) | -$0.92 | — | -9.5% |
| EPS (Diluted) | -$0.92 | — | -9.5% |
| — |
| Total Liabilities | $322.9M | — | — |
| Stockholders' Equity | $17.0M | -71.4% | -88.6% |